Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SLP +9.7%
M&A news:
- RCII +16.6% (confirms receipt of letter from Vintage Capital Management to acquire 100% of the common stock in a go-private transaction for $15.00/share)
Other news:
- FOLD +31.9% (plans to submit a new drug application to the FDA for the oral precision medicine migalastat for Fabry disease in the fourth quarter of 2017)
- RWLK +17.9% (signed a new, exclusive distribution agreement in France with Harmonie Médical Service)
- OCUL +15.6% (Ocular Therapeutix submits details of a manufacturing equipment change as an amendment to the NDA resubmission for DEXTENZA 0.4 mg, for intracanalicular use, for the treatment of ocular pain following ophthalmic surgery currently under review by FDA )
- DRYS +14.7% ( announces motion for temporary restraining order to suspend further issuances of common shares below a certain price was denied)
- NEOT +12.8% (NeoThetics to initiate process to explore and review strategic alternatives focusing on seeking an acquisition, business combination or partnership )
- EVGN +9.6% (demonstrates 'positive Fusarium resistance results with Evogene discovered genes' in its collab w/ Monsanto)
- ITEK +8.4% (modestly rebounding following yesterday's declines)
- ZN +6.9% (continued weakness)
- WMLP +4.8% (after spiking approx 1 point/50% higher in late trade)
- DRRX +2.5% (granted orphan designation by the FDA for its compound for the treatment of primary sclerosing cholangitis)
- BMRN +2.4% (provides update to Phase 1/2 study of BMN 270)
- NVCR +1.4% (CEO featured on Monday's Mad Money)
- ALGT +0.9% (reports June data and updates capacity, TRASM, CASM guidance)
Analyst comments:
- ICPT +3.6% (initiated with Buy at Jefferies )
- PRTA +3% (initiated with Buy at Jefferies )
- VRTX +1% (initiated with Buy at Jefferies )
- XOM +0.5% (upgraded to Overweight from Equal Weight at Barclays)